Elad Sharon, Clinical and Translational Director, Immunotherapy Toxicity Program at Dana-Farber Cancer Institute and Co-Chair, Alliance Immuno-Oncology Committee at Alliance for Clinical Trials in Oncology, shared a post on X:
“Final panel of the Friends of Cancer Research Annual Meeting (FriendsAM25) here in DC! Exciting discussion on control arm selection for multi-regional trials! You can watch live and even ask questions.”
More posts featuring Elad Sharon.